Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics

Ocular Therapeutix, Inc. (OCUL): $4.15

-0.98 (-19.10%)

POWR Rating

Component Grades













Add OCUL to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where OCUL ranks best; there it ranks ahead of 61.74% of US stocks.
  • The strongest trend for OCUL is in Stability, which has been heading up over the past 177 days.
  • OCUL ranks lowest in Growth; there it ranks in the 16th percentile.

OCUL Stock Summary

  • OCUL's price/sales ratio is 8.14; that's higher than the P/S ratio of 86.65% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, OCULAR THERAPEUTIX INC is reporting a growth rate of -73.18%; that's higher than just 19.53% of US stocks.
  • Revenue growth over the past 12 months for OCULAR THERAPEUTIX INC comes in at 54.6%, a number that bests 83.08% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to OCULAR THERAPEUTIX INC, a group of peers worth examining would be VLD, UTHR, MRAM, PTE, and FORM.
  • Visit OCUL's SEC page to see the company's official filings. To visit the company's web site, go to www.ocutx.com.

OCUL Valuation Summary

  • OCUL's price/sales ratio is 8.2; this is 331.58% higher than that of the median Healthcare stock.
  • Over the past 99 months, OCUL's EV/EBIT ratio has gone up 0.2.

Below are key valuation metrics over time for OCUL.

Stock Date P/S P/B P/E EV/EBIT
OCUL 2022-09-23 8.2 6.2 -12.5 -12.8
OCUL 2022-09-22 8.8 6.7 -13.5 -14.1
OCUL 2022-09-21 9.0 6.8 -13.8 -14.4
OCUL 2022-09-20 9.4 7.2 -14.5 -15.3
OCUL 2022-09-19 9.3 7.1 -14.3 -15.0
OCUL 2022-09-16 9.1 6.9 -13.9 -14.5

OCUL Growth Metrics

    The 2 year revenue growth rate now stands at 678.15%.
  • Its 4 year revenue growth rate is now at 250.11%.
  • Its 5 year revenue growth rate is now at 250.11%.
Over the past 33 months, OCUL's revenue has gone up $47,439,000.

The table below shows OCUL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 49.914 -57.611 -32.501
2022-03-31 49.366 -66.791 -22.216
2021-12-31 43.522 -65.55 -6.553
2021-09-30 38.562 -56.643 -88.315
2021-06-30 32.285 -57.319 -102.916
2021-03-31 22.136 -52.059 -131.003

OCUL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCUL has a Quality Grade of C, ranking ahead of 60.31% of graded US stocks.
  • OCUL's asset turnover comes in at 0.155 -- ranking 219th of 682 Pharmaceutical Products stocks.
  • CASI, ONVO, and DRNA are the stocks whose asset turnover ratios are most correlated with OCUL.

The table below shows OCUL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.155 0.903 -1.479
2021-03-31 0.125 0.903 -1.953
2020-12-31 0.129 0.880 -2.245
2020-09-30 0.138 0.818 -1.315
2020-06-30 0.084 0.642 -1.377
2020-03-31 0.077 0.525 -1.196

OCUL Price Target

For more insight on analysts targets of OCUL, see our OCUL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.43 Average Broker Recommendation 1.43 (Moderate Buy)

OCUL Stock Price Chart Interactive Chart >

Price chart for OCUL

OCUL Price/Volume Stats

Current price $4.15 52-week high $12.50
Prev. close $5.13 52-week low $2.91
Day low $4.15 Volume 3,179,600
Day high $5.28 Avg. volume 674,959
50-day MA $5.22 Dividend yield N/A
200-day MA $4.91 Market Cap 319.41M

Ocular Therapeutix, Inc. (OCUL) Company Bio

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.

OCUL Latest News Stream

Event/Time News Detail
Loading, please wait...

OCUL Latest Social Stream

Loading social stream, please wait...

View Full OCUL Social Stream

Latest OCUL News From Around the Web

Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Aytu BioScience (AYTU) and Aquestive Therapeutics (AQST)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCUL – Research Report), Aytu BioScience (AYTU – Research Report) and Aquestive Therapeutics (AQST – Research Report) with bullish sentiments. Ocular Therapeutix (OCUL) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix, with a price target of $10.00. The company's shares closed last Tuesday at $4.31, close to its 52-week low of $2.91. According to TipRanks.

Christine Brown on TipRanks | September 28, 2022

JMP Securities Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Ocular Therapeutix (OCUL - Research Report) today and set a price target of $25.00. The company's shares closed yesterday at $5.28.Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -8.3% and a 35.56% success rate on recommended stocks. Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $16.67.See the top stocks recommended by analysts >>Based on Ocular Therapeutix's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12.

Catie Powers on TipRanks | September 27, 2022

Ocular Therapeutics’ (NASDAQ:OCUL) Wet AMD Interim Phase 1 Data Shows Promise

Ocular Therapeutics (NASDAQ:OCUL) has reported positive interim 7-month data for the Phase 1 trial of its implant (OTX-TKI) being developed for wet age-related macular degeneration (Wet AMD) as well as other retinal ailments. OTX-TKI demonstrated a favorable safety profile, was well tolerated and a detailed presentation of the data is expected on Friday at the American Academy of Ophthalmology (AAO) 2022 annual meeting. Wet AMD affects about 14 million people worldwide and is a leading cause of blindness.

Kailas Salunkhe on TipRanks | September 27, 2022

Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea

Ocular Therapeutix Inc (NASDAQ: OCUL) announced interim 7-month data from its U.S. Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration (wet AMD) and other retinal diseases. Interim data showed that the single OTX-TKI implant was generally well tolerated with a favorable safety profile. No drug-related ocular or systemic serious adverse events (SAEs) were observed. After the mandated aflibercept injection, one SAE of endophthalmitis was observed in the OTK-TKI arm. Single OT

Yahoo | September 27, 2022

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

BEDFORD, Mass, September 27, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. The data wi

Yahoo | September 27, 2022

Read More 'OCUL' Stories Here

OCUL Price Returns

1-mo -21.40%
3-mo 1.47%
6-mo -20.50%
1-year -59.98%
3-year 33.87%
5-year -34.13%
YTD -40.46%
2021 -66.33%
2020 424.05%
2019 -0.75%
2018 -10.56%
2017 -46.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6312 seconds.